According to 2 large breast cancer trials, CYP2D6 genotyping was not predictive of the effectiveness of tamoxifen in postmenopausal women. Thus, the results of these studies are not generalizable to premenopausal women.
With this issue, we introduce the 4 finalists for the second annual Oncology Nurse Excellence award. The 4 finalists—Darcie Deaver, MSN, NP-C; Wendy Miano, RN, MSN, DNP, DN; Patricia (Patti) Palmer, RN, MS, AOCN; and Deborah Thompson, BSN, ONC—were selected from among the many nominations we received. Given the caliber of all the nominees, it was very difficult to narrow it down to just 4 finalists. Read More ›
Because skin is the largest organ in the body, is it not surprising that skin cancer is the most common of all cancers. Melanoma, the most deadly skin cancer, is caused by overexposure to ultraviolet radiation. So with spring in the air and summer right around the corner, let us dig deeper into the statistics surrounding this fatal disease.
Melanoma accounts for about 4% of all skin cancer cases but 79% of all skin cancer deaths.
The term “chemo brain” was coined to describe mild cognitive problems in cancer patients attributed to chemotherapy. Although minor chemotherapy-induced memory and cognitive impairments have been described previously, a case-cohort study suggests that these effects can persist more than 20 years posttherapy.
Primary gastrointestinal stromal tumor (GIST) sited outside the gastrointestinal (GI) tract carries a poorer prognosis than primary GIST within the GI tract, according to a study presented at the recent ASCO GI Symposium in January 2012.
In patients with chronic kidney disease (CKD), decreasing glomerular filtration rate (GFR) is associated with increased risk of kidney and urothelial cancer in a step-wise fashion, according to a large community-based study. An adjusted multivariate analysis found a 2-fold increase in risk of renal cancer and a substantially increased risk of urothelial cancer at GFR <30 mL/min/1.73 m2. The study was presented at the 2012 ASCO Genitourinary Cancers Symposium, held February 2-4 in San Francisco, California.
The previous installment in this cancer care series examined the growing importance of oral therapies for the treatment of cancer and the implications of patient adherence on its success. At the present time, more than 20 oral medications are approved by the Food and Drug Administration (FDA) for first-line treatment of cancer. Read More ›
As many as 1 in 5 cancer patients may experience obstacles in their care, according to a new study published in the Journal of Clinical Oncology. These obstacles include communication issues between patients and their healthcare providers, along with traditional medical errors.
To sign up for our newsletter or print publications, please enter your contact information below.
